Lapatinib Plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience

Breast Care - Switzerland
doi 10.1159/000346829
Full Text
Abstract

Available in full text

Categories
SurgeryOncology
Date
Authors
Publisher

S. Karger AG

Related search

Lapatinib Plus Capecitabine in Women With HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

Oncologist
Cancer ResearchMedicineOncology
2010English

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2013English

Preliminary Safety Data of Preoperative Chemotherapy Plus Trastuzumab, Lapatinib or Both in HER2-positive Operable Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2007English

Phase I Study of Intermittent High Dose Lapatinib Alternating With Capecitabine for HER2-positive Breast Cancer Patients With Central Nervous System Metastases

Clinical Cancer Research
Cancer ResearchOncology
2019English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Optimal Treatment of Early Stage HER2-positive Breast Cancer

Cancer
Cancer ResearchOncology
2018English

HER2-positive Breast Cancer With Brain Metastasis, Long Responder to Lapatinib Therapy

AboutOpen
2018English

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy